Business
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO TAT on March 16, 2026 Approximately $555 million in cash, cash equivalents and investments at end of Q4 2025 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWI
About this update from Relay Therapeutics, Inc.
[{"type":"image","alt":"Relay Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Relay Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":131,"url":"https://media.zenfs.com/en/globenewswire.com/9a37786351f2b419db7f6dccc70bf15f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/72gHEfz4t_5HUyuI4BjnpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9a37786351f2b419db7f6dccc70bf15f","width":300,"height":131}},"lazy":false},{"type":"text","content":"Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026","length":118,"tagName":"p"},{"type":"text","content":"Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 ","length":87,"tagName":"p"},{"type":"text","content":"Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO TAT on March 16, 2026","length":160,"tagName":"p"},{"type":"text","content":"Approximately $555 million in cash, cash equivalents and investments at end of Q4 2025","length":86,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today reported fourth quarter and full year 2025 financial results and 2026 guidance.","length":338,"tagName":"p"},{"type":"text","content":"“Our focus on disciplined execution to date has strengthened the foundation of Relay, aligning our organization to support long-term success. In 2026, Relay is entering a pivotal period defined by multiple upcoming clinical milestones across our zovegalisib program, which recently received Breakthrough Therapy designation from the FDA,” said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. “We anticipate presenting Phase 1/2 breast cancer data at the upcoming ESMO TAT Congress, reporting initial data in PIK3CA-driven vascular anomalies, and providing updates on our breast cancer triplet data and frontline Phase 3 development plans. These milestones position us to deliver meaningful updates in areas with significant unmet...